ARCHIVES

FDA Advisors Give Dox-SL Conditional Approval; Ok Zoladex

This article is from The Cancer Letter archive.

Vol. 21 No. 08 | February 24, 1995

Download PDF Visit The Full Archive

Related Articles

Sacharin Issue Splits Scientists; ACS Proposes Delaney Changes

April 15, 1977

ASCO Annual Meeting: New Approaches For Treatment of Hematologic Malignancies

June 30, 2006

Lymphedema Education Helps Reduce Symptoms, Study Finds

August 28, 2009

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

January 27, 2012

The President’s Cancer Panel publishes its annual report

May 6, 2011

Amgen Web Site For Patients Goes Dark After Story In The Cancer Letter.

November 16, 2007